AU2013215549B2 - Novel morpholinyl derivatives useful as MOGAT-2 inhibitors - Google Patents

Novel morpholinyl derivatives useful as MOGAT-2 inhibitors Download PDF

Info

Publication number
AU2013215549B2
AU2013215549B2 AU2013215549A AU2013215549A AU2013215549B2 AU 2013215549 B2 AU2013215549 B2 AU 2013215549B2 AU 2013215549 A AU2013215549 A AU 2013215549A AU 2013215549 A AU2013215549 A AU 2013215549A AU 2013215549 B2 AU2013215549 B2 AU 2013215549B2
Authority
AU
Australia
Prior art keywords
compound
add
mixture
ethyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013215549A
Other languages
English (en)
Other versions
AU2013215549A1 (en
Inventor
Maria Carmen Fernandez
Maria Rosario Gonzalez-Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48905712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013215549(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013215549A1 publication Critical patent/AU2013215549A1/en
Application granted granted Critical
Publication of AU2013215549B2 publication Critical patent/AU2013215549B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013215549A 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as MOGAT-2 inhibitors Ceased AU2013215549B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12382037 2012-01-31
EP12382037.5 2012-01-31
US201261617093P 2012-03-29 2012-03-29
US61/617,093 2012-03-29
EP12382433.6 2012-11-06
EP12382433 2012-11-06
PCT/US2013/022828 WO2013116065A1 (en) 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as mogat-2 inhibitors

Publications (2)

Publication Number Publication Date
AU2013215549A1 AU2013215549A1 (en) 2014-07-17
AU2013215549B2 true AU2013215549B2 (en) 2015-09-03

Family

ID=48905712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013215549A Ceased AU2013215549B2 (en) 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as MOGAT-2 inhibitors

Country Status (23)

Country Link
US (1) US8993568B2 (enExample)
EP (1) EP2809661B1 (enExample)
JP (1) JP5852269B2 (enExample)
KR (1) KR20140107641A (enExample)
CN (1) CN104080777B (enExample)
AP (1) AP2014007793A0 (enExample)
AU (1) AU2013215549B2 (enExample)
BR (1) BR112014018712A8 (enExample)
CA (1) CA2859992A1 (enExample)
CL (1) CL2014001862A1 (enExample)
CO (1) CO7020914A2 (enExample)
CR (1) CR20140325A (enExample)
DO (1) DOP2014000177A (enExample)
EA (1) EA024182B1 (enExample)
ES (1) ES2571577T3 (enExample)
GT (1) GT201400169A (enExample)
IL (1) IL233542A0 (enExample)
MX (1) MX2014008604A (enExample)
PE (1) PE20141789A1 (enExample)
PH (1) PH12014501712A1 (enExample)
SG (1) SG11201404508XA (enExample)
WO (1) WO2013116065A1 (enExample)
ZA (1) ZA201405227B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
MX2014008604A (es) 2012-01-31 2014-08-22 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2.
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
JPWO2017110841A1 (ja) 2015-12-21 2018-10-11 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078719A1 (en) * 2006-09-28 2009-07-15 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6387954B1 (en) 1998-07-31 2002-05-14 Eli Lilly And Company Alkenyl sulphonamide derivatives
US6500865B1 (en) 1998-07-31 2002-12-31 Eli Lilly And Company Sulfonamide derivatives
GB0408777D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
KR20100097701A (ko) * 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物ｖ
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
MX2014008604A (es) 2012-01-31 2014-08-22 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2.
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078719A1 (en) * 2006-09-28 2009-07-15 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound

Also Published As

Publication number Publication date
CN104080777B (zh) 2015-12-09
ES2571577T3 (es) 2016-05-26
CA2859992A1 (en) 2013-08-08
EP2809661A1 (en) 2014-12-10
CL2014001862A1 (es) 2014-11-14
PH12014501712B1 (en) 2014-10-13
PH12014501712A1 (en) 2014-10-13
EA024182B1 (ru) 2016-08-31
GT201400169A (es) 2015-08-27
PE20141789A1 (es) 2014-11-19
CN104080777A (zh) 2014-10-01
SG11201404508XA (en) 2014-10-30
KR20140107641A (ko) 2014-09-04
WO2013116065A1 (en) 2013-08-08
BR112014018712A8 (pt) 2017-07-11
BR112014018712A2 (enExample) 2017-06-20
HK1199024A1 (zh) 2015-06-19
AP2014007793A0 (en) 2014-07-31
CO7020914A2 (es) 2014-08-11
AU2013215549A1 (en) 2014-07-17
JP2015504917A (ja) 2015-02-16
JP5852269B2 (ja) 2016-02-03
CR20140325A (es) 2014-08-25
DOP2014000177A (es) 2014-08-31
US8993568B2 (en) 2015-03-31
EP2809661B1 (en) 2016-04-06
EA201491227A1 (ru) 2015-01-30
ZA201405227B (en) 2016-05-25
IL233542A0 (en) 2014-08-31
MX2014008604A (es) 2014-08-22
US20150005305A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
EP2809661B1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
CA2596393C (en) 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other conditions
US8575352B2 (en) Benzyl sulfonamide derivatives useful as MOGAT-2 inhibitors
US9073856B2 (en) Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP2011510917A (ja) 新規ｎ−（２−アミノ−フェニル）−アミド誘導体
US9409864B2 (en) Sulfonamide TRPA1 receptor antagonists
EP4065549B1 (en) Cannabinoid derivatives
RS20050805A (sr) Piperidinil-i piperazinil- alkilkarbamatski derivati, dobijanje i njihova terapeutska primena
CN112409376A (zh) 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
JP4809338B2 (ja) 新規なヘキサフルオロイソプロパノール誘導体
AU2013341584A1 (en) Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
JP2022504703A (ja) ピリミジン及びピラジンｈｄａｃ１、２阻害剤
CN111606890A (zh) 含丙烯酰基的核转运调节剂及其用途
CN103833540A (zh) 一种β-取代查尔酮类似物及其制备方法和在制备组蛋白去乙酰化酶抑制剂中的应用
JPH02229168A (ja) ピラゾロン誘導体
WO2020257733A1 (en) Histone demethylase inhibitors for treating cancers
HK1199024B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
Ahamed et al. Synthesis, enzyme assays and molecular docking studies of fluorina ted bioisosteres of santacruzamate A as potential HDAC tracers
CN109232426A (zh) 一种n－羟基－5－取代－1h－吡唑－3－甲酰胺化合物及其制备方法和用途
CN120289417A (zh) 一种化合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired